![Barclay Phillips](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Barclay Phillips
Direktor/Vorstandsmitglied bei
IMMUNIC, INC.
Vermögen: - $ am 31.05.2026
Profil
Barclay A. Phillips currently works at Immunic, Inc., as Lead Independent Director from 2019, Immunic AG, as Member-Supervisory Board, and Ribometrix, Inc., as Chief Operating & Financial Officer from 2020.
Mr. Phillips also formerly worked at Invesco Advisers, Inc., as Director-Private Placements, INVESCO Funds Group, Inc., as Director-Private Placements from 1991 to 1999, CancerVax Corp., as Director from 2000 to 2006, Acorda Therapeutics, Inc., as Director, Vector Fund Management LP, as Managing Director from 1999 to 2008, Vector Asset Management, Inc., as Managing Director from 1999 to 2008, Novavax, Inc., as Chief Financial Officer, Treasurer & Senior VP from 2013 to 2017, PaineWebber, Inc., as Principal, Apjohn Ventures LLC, as General Partner, Amgen Rockville, Inc., as Chief Financial Officer & Senior Vice President from 2000 to 2012, Shearson Lehman Hutton, Inc., as Principal, and G1 Therapeutics, Inc., as CFO & Senior VP-Corporate Development from 2017 to 2019.
Mr. Phillips received his undergraduate degree from the University of Colorado Boulder.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMMUNIC, INC. -.--% | 26.05.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Barclay Phillips
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNIC, INC. | Direktor/Vorstandsmitglied | 19.11.2019 |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals in the immunology space | Direktor/Vorstandsmitglied | - |
Ribometrix, Inc.
 Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease | Finanzdirektor/CFO | 04.08.2020 |
Ehemalige bekannte Positionen von Barclay Phillips
| Unternehmen | Position | Ende |
|---|---|---|
| G1 THERAPEUTICS, INC. | Finanzdirektor/CFO | 10.05.2019 |
| NOVAVAX, INC. | Finanzdirektor/CFO | 10.11.2017 |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Develops therapeutics for cancer | Finanzdirektor/CFO | 29.07.2009 |
Vector Asset Management, Inc.
 Vector Asset Management, Inc. Investment ManagersFinance Vector Asset Management invests in later-stage private and public companies in the life sciences and healthcare industries. Specific areas of interest include: biotechnology, pharmaceuticals, medical devices, diagnostics, plant and animal sciences, healthcare services, healthcare information technology and consumer applications of emerging healthcare technologies. They focus on companies that are raising capital in the private markets prior to the point at which they can access the public markets or execute an alternative exit strategy. Vector looks for companies ready to move from development stage to commercially viable operating entities in a relatively short time. The firm also participates in equity transactions involving securities of small- to mid-cap public companies in the life sciences and healthcare area. Most of Vector's investments are negotiated directly with company management. Vector is an active investor and generally leads or co-leads their investments. They usually serve on the Board of Directors of their portfolio companies. Investments range from $5 million to $15 million with an investment horizon of one to three years. | Chief Investment Officer | 30.09.2008 |
Vector Fund Management LP
 Vector Fund Management LP Investment ManagersFinance Vector Fund Management LP is a private company based in Deerfield, IL. | Corporate Officer/Principal | 01.08.2008 |
Ausbildung von Barclay Phillips
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
60
Beziehungen ersten Grades
16
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 16 |
|---|---|
Novavax, Inc.
 Novavax, Inc. BiotechnologyHealth Technology Engages in development of novel recombinant vaccines | Health Technology |
Invesco Advisers, Inc.
 Invesco Advisers, Inc. Investment ManagersFinance Invesco Advisers provides a variety of services across a broad spectrum of investment strategies, sectors and asset classes. The firm utilizes several different methodologies, each predicated on a rigorous, bottom-up, value-oriented security selection process. | Finance |
INVESCO Funds Group, Inc.
 INVESCO Funds Group, Inc. Investment ManagersFinance Part of Invesco Ltd., INVESCO Funds Group, Inc. is a company based in Denver, CO. | Finance |
CancerVax Corp.
 CancerVax Corp. Miscellaneous Commercial ServicesCommercial Services Researches and develops products for the prevention, treatment, and control of cancer | Commercial Services |
Acorda Therapeutics, Inc.
 Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurology therapies | Health Technology |
Vector Fund Management LP
Vector Fund Management LP Investment ManagersFinance Vector Fund Management LP is a private company based in Deerfield, IL. | Finance |
PaineWebber, Inc.
 PaineWebber, Inc. Investment Banks/BrokersFinance Provides stock brokerage and asset management services | Finance |
Apjohn Ventures LLC
 Apjohn Ventures LLC Investment ManagersFinance Apjohn Ventures seeks investment opportunities in companies located in the United States, primarily in Michigan and the Midwest region. The firm focuses on life sciences such as pharmaceuticals, biotechnology, medical devices & diagnostics and healthcare services. It provides financing for early and later stage capital requirements with an investment size ranging from USD 0.5 to 2 million and also makes co-investments. It acts as a lead investor and it takes a seat on the board of directors. | Finance |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Develops therapeutics for cancer | Health Technology |
Shearson Lehman Hutton, Inc.
 Shearson Lehman Hutton, Inc. Investment Banks/BrokersFinance Provides investment banking services | Finance |
Vector Asset Management, Inc.
Vector Asset Management, Inc. Investment ManagersFinance Vector Asset Management invests in later-stage private and public companies in the life sciences and healthcare industries. Specific areas of interest include: biotechnology, pharmaceuticals, medical devices, diagnostics, plant and animal sciences, healthcare services, healthcare information technology and consumer applications of emerging healthcare technologies. They focus on companies that are raising capital in the private markets prior to the point at which they can access the public markets or execute an alternative exit strategy. Vector looks for companies ready to move from development stage to commercially viable operating entities in a relatively short time. The firm also participates in equity transactions involving securities of small- to mid-cap public companies in the life sciences and healthcare area. Most of Vector's investments are negotiated directly with company management. Vector is an active investor and generally leads or co-leads their investments. They usually serve on the Board of Directors of their portfolio companies. Investments range from $5 million to $15 million with an investment horizon of one to three years. | Finance |
G1 Therapeutics, Inc.
 G1 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cancer treatment | Health Technology |
University of Colorado Boulder
 University of Colorado Boulder Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals in the immunology space | Health Technology |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease | Health Technology |
Immunic, Inc.
 Immunic, Inc. Pharmaceuticals: MajorHealth Technology Develops oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases | Health Technology |
